T
Thomas Zander
Researcher at University of Cologne
Publications - 158
Citations - 10005
Thomas Zander is an academic researcher from University of Cologne. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 31, co-authored 124 publications receiving 6844 citations. Previous affiliations of Thomas Zander include Humboldt University of Berlin.
Papers
More filters
Journal ArticleDOI
Comprehensive genomic profiles of small cell lung cancer
Julie George,Jing Shan Lim,Se Jin Jang,Yupeng Cun,Luka Ozretić,Gu Kong,Frauke Leenders,Xin Lu,Lynnette Fernandez-Cuesta,Graziella Bosco,Christian Müller,Ilona Dahmen,Nadine Jahchan,Kwon-Sik Park,Dian Yang,Anthony N. Karnezis,Dedeepya Vaka,Ángela Torres,Maia Segura Wang,Jan O. Korbel,Roopika Menon,Sung-Min Chun,Deokhoon Kim,Matthew D. Wilkerson,Neil Hayes,David Engelmann,Brigitte M. Pützer,Marc Bos,Sebastian Michels,Ignacija Vlasic,Danila Seidel,Berit Pinther,Philipp Schaub,Christian Becker,Janine Altmüller,Jun Yokota,Takashi Kohno,Reika Iwakawa,Koji Tsuta,Masayuki Noguchi,Thomas Muley,Hans Hoffmann,Philipp A. Schnabel,Iver Petersen,Yuan Chen,Alex Soltermann,Verena Tischler,Chang-Min Choi,Yong-Hee Kim,Pierre P. Massion,Yong Zou,Dragana Jovanovic,Milica Kontic,Gavin M. Wright,Prudence A. Russell,Benjamin Solomon,Ina Koch,Michael Lindner,Lucia Anna Muscarella,Annamaria la Torre,John K. Field,Marko Jakopović,Jelena Knezevic,Esmeralda Castaños-Vélez,Luca Roz,Ugo Pastorino,O.T. Brustugun,Marius Lund-Iversen,Erik Thunnissen,Jens Köhler,Martin Schuler,Johan Botling,Martin Sandelin,Montserrat Sanchez-Cespedes,Helga B. Salvesen,Viktor Achter,Ulrich Lang,Magdalena Bogus,Peter M. Schneider,Thomas Zander,Sascha Ansén,Michael Hallek,Jürgen Wolf,Martin Vingron,Yasushi Yatabe,William D. Travis,Peter Nürnberg,Christian Reinhardt,Sven Perner,Lukas C. Heukamp,Reinhard Büttner,Stefan A. Haas,Elisabeth Brambilla,Martin Peifer,Julien Sage,Roman K. Thomas +95 more
TL;DR: This first comprehensive study of somatic genome alterations in SCLC uncovers several key biological processes and identifies candidate therapeutic targets in this highly lethal form of cancer.
Journal ArticleDOI
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer,Lynnette Fernandez-Cuesta,Martin L. Sos,Julie George,Danila Seidel,Lawryn H. Kasper,Dennis Plenker,Frauke Leenders,Ruping Sun,Thomas Zander,Roopika Menon,Mirjam Koker,Ilona Dahmen,Christian Müller,Vincenzo Di Cerbo,Hans Ulrich Schildhaus,Janine Altmüller,Ingelore Baessmann,Christian Becker,Bram De Wilde,Jo Vandesompele,Diana Böhm,Sascha Ansén,Franziska Gabler,Ines Wilkening,Stefanie Heynck,Johannes M. Heuckmann,Xin Lu,Scott L. Carter,Kristian Cibulskis,Shantanu Banerji,Gad Getz,Kwon-Sik Park,Daniel Rauh,Christian Grütter,Matthias Fischer,Laura Pasqualucci,Gavin M. Wright,Zoe Wainer,Prudence A. Russell,Iver Petersen,Yuan Chen,Erich Stoelben,Corinna Ludwig,Philipp A. Schnabel,Hans Hoffmann,Thomas Muley,Michael Brockmann,Walburga Engel-Riedel,Lucia Anna Muscarella,Vito Michele Fazio,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Erik Thunnissen,Egber Smit,Daniëlle A M Heideman,Peter J.F. Snijders,Federico Cappuzzo,C. Ligorio,Stefania Damiani,John K. Field,Steinar Solberg,Odd Terje Brustugun,Marius Lund-Iversen,Jörg Sänger,Joachim H. Clement,Alex Soltermann,Holger Moch,Walter Weder,Benjamin Solomon,Jean-Charles Soria,Pierre Validire,Benjamin Besse,Elisabeth Brambilla,Christian Brambilla,Sylvie Lantuejoul,Philippe Lorimier,Peter M. Schneider,Michael Hallek,William Pao,Matthew Meyerson,Matthew Meyerson,Julien Sage,Jay Shendure,Robert Schneider,Robert Schneider,Reinhard Büttner,Jürgen Wolf,Peter Nürnberg,Sven Perner,Lukas C. Heukamp,Paul K. Brindle,Stefan A. Haas,Roman K. Thomas +94 more
TL;DR: This study implicates histone modification as a major feature of SCLC, reveals potentially therapeutically tractable genomic alterations and provides a generalizable framework for the identification of biologically relevant genes in the context of high mutational background.
Journal ArticleDOI
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas,Alissa C. Baker,Ralph M. Debiasi,Ralph M. Debiasi,Wendy Winckler,Wendy Winckler,Thomas LaFramboise,Thomas LaFramboise,William M. Lin,William M. Lin,Meng Wang,Meng Wang,Whei Feng,Whei Feng,Thomas Zander,Laura E. MacConnaill,Laura E. MacConnaill,Jeffrey C. Lee,Jeffrey C. Lee,Rick Nicoletti,Rick Nicoletti,Charlie Hatton,Charlie Hatton,Mary Goyette,Luc Girard,Kuntal Majmudar,Liuda Ziaugra,Kwok-Kin Wong,Stacey Gabriel,Rameen Beroukhim,Rameen Beroukhim,Michael Peyton,Jordi Barretina,Jordi Barretina,Amit Dutt,Amit Dutt,Caroline Emery,Heidi Greulich,Heidi Greulich,Kinjal Shah,Kinjal Shah,Hidefumi Sasaki,Adi F. Gazdar,John D. Minna,Scott A. Armstrong,Ingo K. Mellinghoff,F. Stephen Hodi,Glenn Dranoff,Paul S. Mischel,Timothy F. Cloughesy,Stan F. Nelson,Linda M. Liau,Kirsten D. Mertz,Kirsten D. Mertz,Mark A. Rubin,Holger Moch,Massimo Loda,William J. Catalona,Jonathan A. Fletcher,Sabina Signoretti,Frederic J. Kaye,Kenneth C. Anderson,George D. Demetri,Reinhard Dummer,Stephan N. Wagner,Meenhard Herlyn,William R. Sellers,William R. Sellers,Matthew Meyerson,Matthew Meyerson,Levi A. Garraway,Levi A. Garraway +71 more
TL;DR: High-throughput genotyping is adapted to query 238 known oncogene mutations across 1,000 human tumor samples and established robust mutation distributions spanning 17 cancer types, offering a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time'.
Journal ArticleDOI
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y. Janjigian,Yelena Y. Janjigian,Kohei Shitara,Markus Moehler,Marcelo Garrido,Pamela Salman,Lin Shen,Lucjan Wyrwicz,Kensei Yamaguchi,Tomasz Skoczylas,Arinilda Silva Campos Bragagnoli,Tianshu Liu,Michael Schenker,Patricio Eduardo Yanez,Mustapha Tehfe,Ruben Dario Kowalyszyn,Michalis V. Karamouzis,Ricardo Bruges,Thomas Zander,Roberto Pazo-Cid,Erika Hitre,Kynan Feeney,James M. Cleary,Valerie Poulart,Dana Cullen,Ming Lei,H. Xiao,Kaoru Kondo,M. Li,Jaffer A. Ajani +29 more
TL;DR: The CheckMate 649 trial as discussed by the authors evaluated first-line programmed cell death (PD)-1 inhibitor-based therapies in gastric, gastro-oesophageal junction, and oesophage alogaryal adenocarcinoma.
Journal ArticleDOI
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss,Martin L. Sos,Danila Seidel,Martin Peifer,Thomas Zander,Johannes M. Heuckmann,Roland T. Ullrich,Roopika Menon,Sebastian Maier,Alex Soltermann,Holger Moch,Patrick Wagener,Florian Fischer,Stefanie Heynck,Mirjam Koker,Jakob Schöttle,Frauke Leenders,Franziska Gabler,Ines Dabow,Silvia Querings,Lukas C. Heukamp,Hyatt Balke-Want,Sascha Ansén,Daniel Rauh,Ingelore Baessmann,Janine Altmüller,Zoe Wainer,Matthew Conron,Gavin M. Wright,Prudence A. Russell,Ben Solomon,Elisabeth Brambilla,Christian Brambilla,Philippe Lorimier,Steinar Sollberg,Odd Terje Brustugun,Walburga Engel-Riedel,Corinna Ludwig,Iver Petersen,Jörg Sänger,Joachim H. Clement,Harry J.M. Groen,Wim Timens,Hannie Sietsma,Erik Thunnissen,Egbert F. Smit,Daniëlle A.M. Heideman,Federico Cappuzzo,C. Ligorio,Stefania Damiani,Michael Hallek,Rameen Beroukhim,William Pao,Bert Klebl,Matthias Baumann,Reinhard Buettner,Karen Ernestus,Erich Stoelben,Jürgen Wolf,Peter Nürnberg,Peter Nürnberg,Sven Perner,Roman K. Thomas +62 more
TL;DR: F focal FGFR1 amplification is common in squamous cell lung cancer and associated with tumor growth and survival, suggesting that FGFR inhibitors may be a viable therapeutic option in this cohort of patients.